Join Growin Stock Community!

Predictive oncology inc.POAI.US Overview

US StockHealthcare
(No presentation for POAI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

POAI AI Insights

POAI Overall Performance

POAI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

POAI Recent Performance

-2.13%

Predictive oncology inc.

0.05%

Avg of Sector

-0.31%

S&P500

POAI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

POAI Key Information

POAI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

POAI Profile

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

Price of POAI

POAI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

POAI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-116.15
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
50.24%
Net Margin
-11581.34%
Revenue Growth (YoY)
-47.20%
Profit Growth (YoY)
-38.39%
3-Year Revenue Growth
-80.05%
3-Year Profit Growth
-31.76%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-116.15
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
50.24%
Net Margin
-11581.34%
Revenue Growth (YoY)
-47.20%
Profit Growth (YoY)
-38.39%
3-Year Revenue Growth
-80.05%
3-Year Profit Growth
-31.76%

  • When is POAI's latest earnings report released?

    The most recent financial report for Predictive oncology inc. (POAI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating POAI's short-term business performance and financial health. For the latest updates on POAI's earnings releases, visit this page regularly.

  • What is the operating profit of POAI?

    According to the latest financial report, Predictive oncology inc. (POAI) reported an Operating Profit of -3.28M with an Operating Margin of -90,750.91% this period, representing a decline of 41.54% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is POAI's revenue growth?

    In the latest financial report, Predictive oncology inc. (POAI) announced revenue of 3.62K, with a Year-Over-Year growth rate of -98.95%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does POAI have?

    As of the end of the reporting period, Predictive oncology inc. (POAI) had total debt of 1.89M, with a debt ratio of 0.6. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does POAI have?

    At the end of the period, Predictive oncology inc. (POAI) held Total Cash and Cash Equivalents of 181.67K, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does POAI go with three margins increasing?

    In the latest report, Predictive oncology inc. (POAI) did not achieve the “three margins increasing” benchmark, with a gross margin of -131%%, operating margin of -90,750.91%%, and net margin of -2,146,264.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess POAI's profit trajectory and future growth potential.

  • Is POAI's EPS continuing to grow?

    According to the past four quarterly reports, Predictive oncology inc. (POAI)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -107.25. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of POAI?

    Predictive oncology inc. (POAI)'s Free Cash Flow (FCF) for the period is -1.65M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 47.88% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.